Status:
NOT_YET_RECRUITING
The OPERa Study: Evaluating QoL After Rectal Cancer Surgery
Lead Sponsor:
Jewish General Hospital
Conditions:
Rectal Cancer
Quality of Life
Eligibility:
All Genders
18+ years
Brief Summary
Advances in rectal cancer management have significantly reduced morbidity and mortality. The most commonly performed operation for rectal cancer is restorative proctectomy (RP), leaving up to 70% with...
Detailed Description
Advances in rectal cancer management have significantly reduced morbidity and mortality. The most commonly performed operation for rectal cancer is restorative proctectomy (RP), leaving up to 70% with...
Eligibility Criteria
Inclusion
- Patients \>18 years with histopathologically confirmed adenocarcinoma of the rectum, defined as tumor ≤15cm from the anal verge who are planned for RP ± neoadjuvant treatment or WW (CRT alone without surgery).
Exclusion
- Metastatic disease at diagnosis;
- Planned for abdominoperineal resection (APR), low Hartmann's or pelvic exenteration (PE);
- Cannot be contacted by telephone;
- Unable to read and comprehend English or French;
- Unable to give clear and informed consent.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2029
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04893876
Start Date
January 1 2023
End Date
September 30 2029
Last Update
August 18 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.